TRADITIONDATA
10.10.2022 13:43:42 CEST | Business Wire | Pressemeddelelse
TraditionDATA, data- og informationsserviceafdelingen hos Compagnie Financière Tradition (Tradition), har udgivet en omfattende skandinavisk datapakke som svar på den stigende efterspørgsel på Traditions markedsførende prisdata i regionen.
Den fulde pakke af skandinaviske data, som indeholder data om valuta (FX), rentederivater (IRD) og inflation, er baseret på en kombination af priser, der tager udgangspunkt i aktiehandler foretaget af Traditions markedsførende mæglere samt deres ekspertanalyser. Dataene er tilgængelige direkte fra TraditionDATA såvel som på Refinitiv under firmaets regionale markedsdatapakker.
Udgivelsen af den skandinaviske datapakke er i tråd med TraditionDATAs mission om at tilbyde mindre, granulære pakker baseret på valuta, region eller produkt, som gør det muligt for kunderne kun at betale for det, de rent faktisk har brug for. Dette er i direkte modsætning til mange af deres konkurrenter, som kun tilbyder større europæiske pakker, som er dyre og tager tid at analysere nærmere, før de kan konverteres til brugbar forretningsindsigt.
Den skandinaviske datapakke giver kunderne mulighed for at analysere:
- FX - spothandler, krydshandler (cross trades), terminshandler på ydelser og produkter og kvartalsindtjening på tværs af DKK, NOK og SEK på det internationale valutamarked
- IRD - basisderivater, krydsvalutaderivater, renteswaps, overnight indexed swaps, terminskursaftaler
- Inflation - forbrugerprisindeksdata om inflation
Udover at tilbyde kunderne avancerede data og ekspertise i den skandinaviske region, muliggør TraditionDATA også streaming i realtid, øjebliksbilleder af dag til dag-renter, adgang til historiske data og fuld integration med eksisterende arbejdsgange.
James Watson, Global Head of Sales hos TraditionDATA, kommenterede: “Hos TraditionDATA ved vi, at der ikke findes to ens virksomheder, og derfor arbejder vi sammen med vores kunder om at udvikle pakker, der er skræddersyede til deres individuelle behov. Vi tror på, at regionale markeder fortsat vil kræve specifikke datasæt, der er lokaliseret til deres overordnede forretningsaktiviteter, og denne tilgang har allerede vist sig at være en stor succes i forbindelse med vores japanske Nihon- og israelske Shekel-pakker. Vi ser frem til at fortsætte med at tilføje nye instrumenter til den skandinaviske pakke og udvide vores regionale markedsdatatilbud i de kommende måneder.”
ENDS
Om TraditionDATA
TraditionDATA tilbyder en varieret og fleksibel tilgang til leverance af markedsdata på tværs af alle aktivklasser på det globale uofficielle børsmarked for derivater.
Ved at tilbyde mindre, mere fokuserede og granulære pakker baseret på valuta, region eller produkt sætter TraditionDATA sine kunder i stand til at betale for netop det, de har brug for, i modsætning til større pakker, der kræver nærmere analyse.
Med over 1 billion datapunkter på tværs af mere end 200 produkter og 186.000 instrumenter, der går mere end 15 år tilbage, samt 43 kontorer i 30 lande, tilbyder TraditionDATA aktører på tværs af det globale finansmarked alle de oplysninger, de har brug for, for at drive deres forretning og tage forretningsmæssige beslutninger, på grundlag af et stadigt voksende datasæt.
TraditionDATA er en del af Tradition (Compagnie Financière Tradition S.A. (SWX: CFT)), en af verdens største børsmæglere inden for finansielle og råvarerelaterede produkter på det uofficielle børsmarked for værdipapirer. Traditions lange historie med administration af prissætning af likviditet og afvikling af handler på tværs af flere aktivklasser med både nye og komplekse produkter på primære og nye vækstmarkeder gør det muligt for TraditionDATA at prisfastsætte finansielle instrumenter på mange af verdens mest omskiftelige markeder, som andre ikke formår.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20221010005055/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
